Conversation Series | Myth Busting about Erectile Dysfunction
This week, Professor Chung shares insights on the common misconceptions about the lived experience of Erectile Dysfunction (ED); myths in relation to treatment of ED, his professional views on the particular issues around the context of men’s sexual health and why he believes SPONTAN® is being welcomed as a potential solution for ED. At LTR […]
LTP Secures Global Co-Development Agreement with Aptar Pharma
LTR Pharma has today announced it has entered into a Comprehensive Co-Development Agreement with Aptar Pharma for SPONTAN® for global markets. APTAR is a global leader in the design and manufacturing of a broad range of drug and consumer product dosing, dispensing and protection technologies. APTAR has substantial FDA regulatory expertise and its delivery systems […]
The West Australian | A Treatment on the Up
LTR Pharma has been featured in The West Australian, in an article titled ‘A Treatment on the Up’ by business journalist Cheyanne Enciso highlighting the significance of Australian patients being the first in the world to access to a PDE5 nasal-spray treatment for erectile dysfunction, SPONTAN®. The article includes comments from Melissa Hadley Barrett, founder […]
SYNTHETIC | Interview with Lee Rodne
LTR Pharma Executive Chairman, Lee Rodne, recently spoke with Simons Chase of Synthetic.com, taking a deep dive into the Company’s future plans to bring SPONTAN, its “first-in-class” rapid onset, on-demand therapeutic nasal spray for the treatment of erectile dysfunction (ED), to the Australian and US markets. Take a look:
SPONTAN® prescribed to first patient under TGA Special Access Scheme
LTR Pharma has today announced that SPONTAN® has been prescribed to the first patients under the TGA’s Special Access Scheme (SAS). Patients were prescribed by the Restorative Sexual Health Clinic (RSHC), which provides evidence-based care to help individuals achieve optimal sexual function and improve intimate relationships. Restorative Sexual Health Clinic’s founder, Melissa Hadley Barrett, said, […]
Ausbiz | Interview with Lee Rodne
Following this week’s announcement of a successful $10.5M capital raise, LTR Pharma’s Executive Chairman, Lee Rodne, spoke with ausbiz about future plans for the commercial launch of fast-acting nasal spray treatment for erectile dysfunction, SPONTAN. Watch the video.
Stockhead Shortz | Interview with Lee Rodne
In an interview with Stockhead‘s Sarah Hughan, LTR Pharma Executive Chairman Lee Rodne spoke of the Company’s successful $10.5 million capital raise, and how the funds would be allocated to fast-track commercialisation of its fast-acting nasal spray treatment for erectile dysfunction (ED), SPONTAN. “We’re scaling up our commercial manufacturing, and getting prepared to launch here […]
The Australian Business Review | LTP Pharma raises $10.5m to advance erectile dysfunction treatment SPONTAN
LTR Pharma’s A$10.5 million share placement has been featured in The Australian Business Review. Click to read the article.
LTR Pharma completes A$10.5 million placement to expedite commercialisation of SPONTAN®
LTR Pharma has today announced that it has successfully completed a A$10.5 million Share Placement to sophisticated and new institutional investors to expedite the commercialisation of SPONTAN®. Funds will be deployed to advance SPONTAN’s regulatory pathways, expand R&D pipeline, and bolster sales and marketing efforts. LTR Pharma Chairman, Lee Rodne, commented: “This capital injection will […]
Conversation Series | Treatment Innovation for ED – Introduction to SPONTAN®
The fourth instalment of the LTR Pharma Conversation Series is now live. This week, Professor Chung shares insights into nasal delivery technology and why it is an effective pathway to treat erectile dysfunction; clinical evidence to support the benefits and mechanism of action of SPONTAN®; and why patients are interested in this new treatment. For […]
The Courier Mail | LTR hard sell not required
Following last week’s announcement of positive results from our SPONTAN® pivotal bioequivalence clinical study, LTR Pharma was featured in The Courier Mail’s City Beat by business reporter Glen Norris over the weekend. Here’s an excerpt: “LTR, which is developing an intranasal spray treatment called SPONTAN, on Friday released data that is expected to support the […]
Small Caps | LTR Pharma’s SPONTAN nasal spray achieves superior results in erectile dysfunction clinical study
LTR Pharma’s successful results from its pivotal bioequivalence clinical study have been featured in Small Caps, highlighting the positive market response to the announcement. Journalist Colin Hay wrote: ” LTR Pharma (ASX: LTP) has come out of a trading halt with the announcement of successful results from a pivotal bioequivalence clinical study into a breakthrough treatment for […]
SPONTAN® achieves positive clinical study results
LTR Pharma (ASX:LTP) has announced extremely positive results from its SPONTAN® pivotal bioequivalence clinical study. Initial analysis has concluded that SPONTAN® achieves rapid absorption and faster onset of action compared to oral PDE5 inhibitors. The results demonstrated that SPONTAN achieves rapid absorption and faster onset of action at a substantially lower dose, compared to traditional […]
Livewire | LTR Pharma – ED & the need for speed
LTR Pharma and SPONTAN have been featured on Livewire Markets in an artucle titled “ED & the need for speed.” In the article, author Thomas Schoenmaker of Alpine Capital presents the market opportunity for innovation in the ED space, and how LTR Pharma is placed to take advantage of this position with SPONTAN. Here’s an […]
Conversation Series | 101 on Erectile Dysfunction
The second episode of the LTR Pharma Conversation Series is now live. This week, Professor Chung shares insights into Erectile Dysfunction (ED); an explanation of the erectile mechanism; how ED is caused; who it impacts (this one might surprise you); and the potential for SPONTAN® to help those with men’s health issues. https://youtu.be/rkoMVtKsAFI
Conversation Series | Meet The Expert – Professor Eric Chung
The first episode of the LTR Pharma Conversation Series is now live. This week, we introduce to you Professor Eric Chung, LTR Pharma Scientific and Clinical Advisor and a consultant urological surgeon. Meet the Expert: Professor Chung is a consultant urological surgeon at the AndroUrology Centre for Sexual, Urinary and Reproductive Excellence and holds professorial […]
Body + Soul | Interview with Professor Eric Chung
LTR Pharma Scientific and Clinical Advisor and consultant urological surgeon, Professor Eric Chung shares insights with Body + Soul to discuss the correlation between performance anxiety and infidelity. In this latest feature, Professor Eric Chung, unpacks the effects of cheating on both partners (the cheater and the cheated) and provides guidance for navigating the aftermath […]
Men’s Health Australia | Interview with Professor Eric Chung
LTR Pharma Scientific and Clinical Advisor and consultant urological surgeon, Professor Eric Chung was recently interviewed by Cayle Reid at Men’s Health Australia to discuss external factors that can influence performance in the bedroom. Professor Chung commented: “Sex is about emotional and physical satisfaction, and both factors can play a significant role in our sexual […]
Quarterly Activities Report and 4C – period ended 31 March 2024
LTR Pharma has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 31 March 2024. Key highlights from this period include: Pivotal clinical study of SPONTAN® fully recruited and completed dosing of all participants. SPONTAN achieved key manufacturing validation and first commercial batch production. SPONTAN is designed […]
SPONTAN® pivotal clinical study completes recruitment and dosing
LTR Pharma has today announced that all patients recruited for its pivotal bioequivalence clinical study of SPONTAN® nasal spray have now received their second and final dose, completing the recruitment and dosing stage of the clinical study. The Study is evaluating the relative bioavailability of SPONTAN, a novel and proprietary PDE5 nasal spray treatment compared […]